About BluMaiden
About BluMaiden
End-to-End Solutions from Microbiome-based AI Discovery Engines
Led by an experienced board and executive team, BluMaiden Biosciences is providing value add outputs for Pharma and Industry players across clinical trials and drug discovery.
Our Expert Network
The BluMaiden Biosciences science team is currently located both in Singapore and Europe. With the founding team located in Singapore, we are backed by a global and ever-expanding expert network through our science advisors, partners, and investors.
Embracing Diversity
Diverse and inclusive teams have a positive impact on our products and services, and help us better serve our partners, employees, and stakeholders from every background. We are constantly learning and iterating, whether through central programs, or work within our business teams, through programs that are local, regional, and global. BluMaiden Biosciences are aware that our current team composition does not fulfil our diversity goals. As an early company, securing expertise and moving the business plan forward fast are important drivers. We are actively recruiting for diverse candidates to fill many board and senior positions.
Board of Directors

Damien Keogh, Ph.D
Director and CEO
Dr. Keogh is the Chief Executive Officer and Founding Member of BluMaiden Biosciences. He has assembled the founding team and recruited a distinguished Board of Directors and Scientific Advisors. Dr. Damien Keogh is a data-driven and innovative scientist with a background in biotechnology, commercialization, and entrepreneurship. Following undergraduate studies in Biotechnology he obtained a PhD in Microbiology

Michael Tillman
Chairman
Mr. Tillmann is a seasoned CEO, board member and entrepreneur with 30 years of experience in the pharmaceutical and diagnostics industry. Mr. Tillmann has a stellar 30-year track-record in the pharmaceutical and diagnostics industry.

Terence A. Kelly, Ph.D
Director
Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is expert in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.

Robert Meyer
Director
Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct investments in early-stage opportunities.

Michael Gorriz
Director
Mr. Gorriz is currently an Independent Non-Executive Director of Mercedes-Benz Automobile Finance Co., Ltd. in China, Non-Executive Director of mox Bank (a virtual bank in Hong Kong), Non-Executive Director of Swiss IT Security AG (an IT security service group based in Switzerland) and Kyberlife (an e-commerce marketplace start-up for life sciences, pharmaceutical, and healthcare industries headquartered in Singapore).
Our Scientific Leadership

Cat Kelly Ph.D
Head of Business Development
Dr Cat Kelly brings over 20 years of experience in biomarker development, clinical trials and drug discovery to BluMaiden Biosciences. Dr. Kelly joins us from Perspectum Ltd, where she founded the imaging CRO analysis function, which has delivered imaging endpoints for over 50 Phase 2 and 3 trials in the fatty liver space. She led the development of Perspectum’s flagship product, LiverMultiScan, a biomarker for liver health, working with stakeholders across biotech, academia and healthcare provision to commercialise and deliver this biomarker to a global customer base. Prior to this, she worked in drug discovery in Cambridge, UK, using AI to predict oral bioavailability of candidate libraries.

Oleg Moskvin Ph.D
Head of Computational Science
Oleg Moskvin, PhD is a computational biologist who brings together experiences and mindsets from network-centric *omics data analysis in both prokaryotic and eukaryotic systems, genome analysis, and classical biochemistry. His academic career involved the discovery of novel functionality in bacterial genomes, and extensive *omics studies related to areas ranging from biofuel research and bacteria-environment interactions to stem cell differentiation, supplemented with the development of related computational approaches. The number of publications that cite Dr. Moskvin’s work exceeds 2,600.

Lakshmanan Lakshmanan
Head of Information Technology
Lakshmanan is a technologist with extensive experience (17+ years) in the designing (solution architecture, product management) and delivering (systems integration, management of data teams) complex software solutions leading to capability uplifts, costs reductions and business process optimizations for Fortune 500 Companies across Banking, Financial services, Retail, Software vendors, digital native, healthcare, and Utilities.

Rohan Williams, Ph.D
Chair of SAB, Computational Bio Expert
Rohan Williams is a computational biologist, specialising in bioinformatics and systems biology of microbiomes and microbial ecology. Following undergraduate studies in Physics he obtained a PhD in Medicine at the University of New South Wales (Sydney, Australia) in the field of human gastrointestinal physiology

Nicholas Talley, Ph.D
Scientific Advisory Board, Member
Distinguished Laureate Professor Nicholas Talley AC is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is based at the University of Newcastle, Australia and held former appointments as Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida, a Professor of Medicine and Professor of Epidemiology at Mayo Clinic and Foundation Professor of Medicine at the University of Sydney, Nepean Hospital.

Damian O’Connell, Ph.D
Scientific Advisory Board, Member
Professor Damian O’Connell is Chief Executive Officer the Experimental Drug Development Centre at A*Star – the Agency for Science, Technology and Research based in Singapore. The Experimental Drug Development Centre is a national platform for drug and biomarker discovery as well as early clinical development.

Kim Lewis, Ph.D Scientific Advisory Board, Member
Professor Kim Lewis is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is a University Distinguished Professor and the Director of Antimicrobial Discovery Center at Northeastern University in Boston, Massachusetts.

Stephen Simpson, Ph.D
Scientific Advisory Board, Member
Professor Stephen Simpson, FRS is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is the Director of the Charles Perkin Centre at the University of Sydney, a Professor in the School of Life and Environmental Sciences at the University of Sydney, and Executive Director of Obesity Australia
End-to-End Deep Domain Expertise
We Have Expertise Across:
List Of Expertise Areas:
- Computational Biology
- Computational Chemistry
- Disease Biology
- Clinical Science
- Information Technology
- Microbiology
- Computational Biology
- Computational Chemistry
- Disease Biology
- Clinical Science
- Information Technology
- Microbiology
- Computational Biology
- Computational Chemistry
- Disease Biology
- Clinical Science
- Information Technology
- Microbiology
Our Vision And Mission
Unlocking the potential of human microbiome with deep tech
The answer to human health lies within our own body. The human microbiome has co-evolved with human populations through millennia and has developed powerful ways to regulate human health through secreted signaling molecules. This reservoir of microbiome-derived compounds, naturally found and working in our own bodies, offers a safer and more efficient way to improve health, but remains largely untapped. Backed by our investors, advisory boards and partners, the BluMaiden team is on a mission to uncover the intricate connection between microbiome signals and human health for the development of therapeutics, diagnostics, and digital health technologies.
Our Values
1. Pioneering Spirit
+ We venture beyond boundaries to tackle unmet needs in new ways
+ Dare to think differently to change the status quo
+ Innovative integrated platform technology and analytics streamlines the road to drug discovery.
2. Holistic Point of View
+ Big picture thinkers who invest in the outcomes
+ We’ve integrated data capture, analysis, and discovery for a seamless drug discovery process
+ Seek partnerships and effective co-creation with consumers and pharma companies
3. Uphold Excellence
+ Pursue a high level of intellectual and scientific rigor
+ Welcome obstacles and challenges as opportunities to improve and innovate
+ We invest in people, the foundation of an enduring company
4. Do Right
+ We own our actions
+ Act with conviction, compassion and empathy
+ Uphold a high ethical conduct in our research and process
+ Dedicated to the science and better outcomes for all
Code of Conduct
We strongly believe that compliance & ethics are essential to preserve and strengthen the trust of our patients, business partners, shareholders and communities. We ensure transparency in all aspects of our business operation, conduct ourselves at all times in accordance with our vision and values as outlined in our Code of Conduct, and hold ourselves accountable for meeting the expectations we place on ourselves.